Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.

Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C, Hengstschläger M, Eferl R, Moriggl R, Sommergruber W, Gerner C, Dolznig H.

Angiogenesis. 2019 Oct 30. doi: 10.1007/s10456-019-09688-8. [Epub ahead of print]

PMID:
31667643
2.

Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis.

Katholnig K, Schütz B, Fritsch SD, Schörghofer D, Linke M, Sukhbaatar N, Matschinger JM, Unterleuthner D, Hirtl M, Lang M, Herac M, Spittler A, Bergthaler A, Schabbauer G, Bergmann M, Dolznig H, Hengstschläger M, Magnuson MA, Mikula M, Weichhart T.

JCI Insight. 2019 Oct 17;4(20). pii: 124164. doi: 10.1172/jci.insight.124164.

3.

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2019 Aug 13;10(8):605. doi: 10.1038/s41419-019-1853-1.

4.

Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.

Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.

5.

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

6.

Exclusion from spheroid formation identifies loss of essential cell-cell adhesion molecules in colon cancer cells.

Stadler M, Scherzer M, Walter S, Holzner S, Pudelko K, Riedl A, Unger C, Kramer N, Weil B, Neesen J, Hengstschläger M, Dolznig H.

Sci Rep. 2018 Jan 18;8(1):1151. doi: 10.1038/s41598-018-19384-0.

7.

Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro.

Holzner S, Brenner S, Atanasov AG, Senfter D, Stadler S, Nguyen CH, Fristiohady A, Milovanovic D, Huttary N, Krieger S, Bago-Horvath Z, de Wever O, Tentes I, Özmen A, Jäger W, Dolznig H, Dirsch VM, Mader RM, Krenn L, Krupitza G.

Food Chem Toxicol. 2018 Jan;111:114-124. doi: 10.1016/j.fct.2017.11.015. Epub 2017 Nov 10.

PMID:
29129665
8.

Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression.

Kramer N, Schmöllerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, Scherzer M, Riedl A, Artaker M, Crncec I, Lenhardt D, Schwarz T, Prieler B, Han X, Hengstschläger M, Schüler J, Eferl R, Moriggl R, Sommergruber W, Dolznig H.

Oncogene. 2017 Sep 28;36(39):5460-5472. doi: 10.1038/onc.2017.144. Epub 2017 May 29.

PMID:
28553956
9.

Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

Unger C, Kramer N, Unterleuthner D, Scherzer M, Burian A, Rudisch A, Stadler M, Schlederer M, Lenhardt D, Riedl A, Walter S, Wernitznig A, Kenner L, Hengstschläger M, Schüler J, Sommergruber W, Dolznig H.

Oncogene. 2017 Sep 21;36(38):5341-5355. doi: 10.1038/onc.2017.116. Epub 2017 May 22.

PMID:
28534511
10.

An Optimized 3D Coculture Assay for Preclinical Testing of Pro- and Antiangiogenic Drugs.

Unterleuthner D, Kramer N, Pudelko K, Burian A, Hengstschläger M, Dolznig H.

SLAS Discov. 2017 Jun;22(5):602-613. doi: 10.1177/2472555216686529. Epub 2017 Jan 31.

PMID:
28346097
11.

Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3.

Friedrich K, Dolznig H, Han X, Moriggl R.

Biosci Trends. 2017 Mar 22;11(1):1-8. doi: 10.5582/bst.2016.01250. Epub 2017 Feb 2. Review.

12.

Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling.

Stadler S, Nguyen CH, Schachner H, Milovanovic D, Holzner S, Brenner S, Eichsteininger J, Stadler M, Senfter D, Krenn L, Schmidt WM, Huttary N, Krieger S, Koperek O, Bago-Horvath Z, Brendel KA, Marian B, de Wever O, Mader RM, Giessrigl B, Jäger W, Dolznig H, Krupitza G.

Cell Mol Life Sci. 2017 May;74(10):1907-1921. doi: 10.1007/s00018-016-2441-5. Epub 2016 Dec 24.

13.

Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro.

Holzner S, Senfter D, Stadler S, Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S, Jäger W, Dolznig H, Mader RM, Krupitza G.

Oncol Rep. 2016 Nov;36(5):3065-3071. doi: 10.3892/or.2016.5114. Epub 2016 Sep 20.

PMID:
27666412
14.

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Erratum in: Cell Death Dis. 2018 Jul 23;9(8):800. Retraction in: Cell Death Dis. 2019 Aug 13;10(8):605.

15.

Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.

Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, Pfeiffer D, Krupitza G, Dolznig H.

J Cell Sci. 2017 Jan 1;130(1):203-218. doi: 10.1242/jcs.188102. Epub 2016 Sep 23.

16.

Genetics of the human placenta: implications for toxicokinetics.

Gundacker C, Neesen J, Straka E, Ellinger I, Dolznig H, Hengstschläger M.

Arch Toxicol. 2016 Nov;90(11):2563-2581. Epub 2016 Sep 6. Review.

PMID:
27600793
17.

12(S)-HETE increases intracellular Ca(2+) in lymph-endothelial cells disrupting their barrier function in vitro; stabilization by clinical drugs impairing calcium supply.

Nguyen CH, Brenner S, Huttary N, Li Y, Atanasov AG, Dirsch VM, Holzner S, Stadler S, Riha J, Krieger S, Milovanovic D, Fristiohardy A, Simonitsch-Klupp I, Dolznig H, Saiko P, Szekeres T, Giessrigl B, Jäger W, Krupitza G.

Cancer Lett. 2016 Sep 28;380(1):174-83. doi: 10.1016/j.canlet.2016.06.022. Epub 2016 Jul 4.

PMID:
27390016
18.

Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching.

Nguyen CH, Stadler S, Brenner S, Huttary N, Krieger S, Jäger W, Dolznig H, Krupitza G.

Br J Cancer. 2016 Jul 26;115(3):364-70. doi: 10.1038/bjc.2016.201. Epub 2016 Jun 30.

19.

The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.

Oncotarget. 2016 Aug 9;7(32):51096-51106. doi: 10.18632/oncotarget.9315. Erratum in: Oncotarget. 2018 Sep 18;9(73):33865.

20.

Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Oct 26;6:8802. doi: 10.1038/ncomms9802. No abstract available.

PMID:
26499136
21.

Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment.

Stadler M, Walter S, Walzl A, Kramer N, Unger C, Scherzer M, Unterleuthner D, Hengstschläger M, Krupitza G, Dolznig H.

Semin Cancer Biol. 2015 Dec;35:107-24. doi: 10.1016/j.semcancer.2015.08.007. Epub 2015 Aug 28. Review.

PMID:
26320002
22.

The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.

Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Phytomedicine. 2015 Aug 15;22(9):862-74. doi: 10.1016/j.phymed.2015.06.003. Epub 2015 Jun 26.

PMID:
26220634
23.

STAT3 regulated ARF expression suppresses prostate cancer metastasis.

Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L.

Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. Erratum in: Nat Commun. 2015;6:8802.

24.

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.

Schreiber-Brynzak E, Klapproth E, Unger C, Lichtscheidl-Schultz I, Göschl S, Schweighofer S, Trondl R, Dolznig H, Jakupec MA, Keppler BK.

Invest New Drugs. 2015 Aug;33(4):835-47. doi: 10.1007/s10637-015-0260-4. Epub 2015 Jun 21.

PMID:
26091914
25.

High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.

Rudisch A, Dewhurst MR, Horga LG, Kramer N, Harrer N, Dong M, van der Kuip H, Wernitznig A, Bernthaler A, Dolznig H, Sommergruber W.

PLoS One. 2015 Apr 28;10(4):e0124283. doi: 10.1371/journal.pone.0124283. eCollection 2015.

26.

Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.

Senfter D, Holzner S, Kalipciyan M, Staribacher A, Walzl A, Huttary N, Krieger S, Brenner S, Jäger W, Krupitza G, Dolznig H, Mader RM.

Hum Mol Genet. 2015 Jul 1;24(13):3689-98. doi: 10.1093/hmg/ddv113. Epub 2015 Apr 1.

PMID:
25832648
27.

An open data ecosystem for cell migration research.

Masuzzo P, Martens L; 2014 Cell Migration Workshop Participants, Ampe C, Anderson KI, Barry J, De Wever O, Debeir O, Decaestecker C, Dolznig H, Friedl P, Gaggioli C, Geiger B, Goldberg IG, Horn E, Horwitz R, Kam Z, Le Dévédec SE, Vignjevic DM, Moore J, Olivo-Marin JC, Sahai E, Sansone SA, Sanz-Moreno V, Strömblad S, Swedlow J, Textor J, Van Troys M, Zantl R.

Trends Cell Biol. 2015 Feb;25(2):55-8. doi: 10.1016/j.tcb.2014.11.005. Epub 2014 Dec 5.

PMID:
25484346
28.

Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development.

Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M, Dolznig H.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:50-67. doi: 10.1016/j.addr.2014.10.015. Epub 2014 Oct 23. Review.

PMID:
25453261
29.

Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.

Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):994-1006. doi: 10.1016/j.canlet.2014.11.019. Epub 2014 Nov 15.

PMID:
25444930
30.

Pharmacological insight into the anti-inflammatory activity of sesquiterpene lactones from Neurolaena lobata (L.) R.Br. ex Cass.

McKinnon R, Binder M, Zupkó I, Afonyushkin T, Lajter I, Vasas A, de Martin R, Unger C, Dolznig H, Diaz R, Frisch R, Passreiter CM, Krupitza G, Hohmann J, Kopp B, Bochkov VN.

Phytomedicine. 2014 Oct 15;21(12):1695-701. doi: 10.1016/j.phymed.2014.07.019. Epub 2014 Sep 15.

PMID:
25442279
31.

Reliable quantification of protein expression and cellular localization in histological sections.

Schlederer M, Mueller KM, Haybaeck J, Heider S, Huttary N, Rosner M, Hengstschläger M, Moriggl R, Dolznig H, Kenner L.

PLoS One. 2014 Jul 11;9(7):e100822. doi: 10.1371/journal.pone.0100822. eCollection 2014.

32.

The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays.

Walzl A, Unger C, Kramer N, Unterleuthner D, Scherzer M, Hengstschläger M, Schwanzer-Pfeiffer D, Dolznig H.

J Biomol Screen. 2014 Aug;19(7):1047-59. doi: 10.1177/1087057114532352. Epub 2014 Apr 23.

PMID:
24758920
33.

IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction.

Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, Artaker M, Nivarthi H, Moriggl R, Hengstschläger M, Kerjaschki D, Sommergruber W, Dolznig H, Garin-Chesa P.

Oncogene. 2015 Feb 12;34(7):815-25. doi: 10.1038/onc.2014.18. Epub 2014 Mar 17.

PMID:
24632618
34.

Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model.

Teichmann M, Kretschy N, Kopf S, Jarukamjorn K, Atanasov AG, Viola K, Giessrigl B, Saiko P, Szekeres T, Mikulits W, Dirsch VM, Huttary N, Krieger S, Jäger W, Grusch M, Dolznig H, Krupitza G.

Arch Toxicol. 2014 Mar;88(3):691-9. doi: 10.1007/s00204-013-1183-5. Epub 2013 Dec 19.

PMID:
24352538
35.

Drug resistance mediated changes in lymphendothelial tumor cell intravasation.

Senfter D, Huttary N, Krupitza G, Dolznig H, Mader RM.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):82-4. doi: 10.5414/CPXCES13EA04. No abstract available.

PMID:
24321211
36.

In vitro characterisation of the anti-intravasative properties of the marine product heteronemin.

Kopf S, Viola K, Atanasov AG, Jarukamjorn K, Rarova L, Kretschy N, Teichmann M, Vonach C, Saiko P, Giessrigl B, Huttary N, Raab I, Krieger S, Schumacher M, Diederich M, Strnad M, de Martin R, Szekeres T, Jäger W, Dirsch VM, Mikulits W, Grusch M, Dolznig H, Krupitza G.

Arch Toxicol. 2013 Oct;87(10):1851-61. doi: 10.1007/s00204-013-1045-1. Epub 2013 Mar 30.

PMID:
23543012
37.

Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis.

Viola K, Kopf S, Rarova L, Jarukamjorn K, Kretschy N, Teichmann M, Vonach C, Atanasov AG, Giessrigl B, Huttary N, Raab I, Krieger S, Strnad M, de Martin R, Saiko P, Szekeres T, Knasmüller S, Dirsch VM, Jäger W, Grusch M, Dolznig H, Mikulits W, Krupitza G.

Arch Toxicol. 2013 Jul;87(7):1301-12. doi: 10.1007/s00204-013-1028-2. Epub 2013 Mar 17.

PMID:
23503627
38.

In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen.

Kretschy N, Teichmann M, Kopf S, Atanasov AG, Saiko P, Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, Krieger S, Jäger W, Szekeres T, Nijman SM, Mikulits W, Dirsch VM, Dolznig H, Grusch M, Krupitza G.

Br J Cancer. 2013 Feb 19;108(3):570-8. doi: 10.1038/bjc.2012.580. Epub 2013 Jan 8.

39.

The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis.

Unger C, Popescu R, Giessrigl B, Laimer D, Heider S, Seelinger M, Diaz R, Wallnöfer B, Egger G, Hassler M, Knöfler M, Saleh L, Sahin E, Grusch M, Fritzer-Szekeres M, Dolznig H, Frisch R, Kenner L, Kopp B, Krupitza G.

Int J Oncol. 2013 Jan;42(1):338-48. doi: 10.3892/ijo.2012.1690. Epub 2012 Nov 6.

PMID:
23135783
40.

Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion.

Viola K, Kopf S, Huttary N, Vonach C, Kretschy N, Teichmann M, Giessrigl B, Raab I, Stary S, Krieger S, Keller T, Bauer S, Hantusch B, Szekeres T, de Martin R, Jäger W, Mikulits W, Dolznig H, Krupitza G, Grusch M.

Br J Cancer. 2013 Feb 19;108(3):564-9. doi: 10.1038/bjc.2012.485. Epub 2012 Oct 23.

41.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

42.

In vitro cell migration and invasion assays.

Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M, Dolznig H.

Mutat Res. 2013 Jan-Mar;752(1):10-24. doi: 10.1016/j.mrrev.2012.08.001. Epub 2012 Aug 23. Review.

PMID:
22940039
43.

Amniotic fluid stem cell-based models to study the effects of gene mutations and toxicants on male germ cell formation.

Gundacker C, Dolznig H, Mikula M, Rosner M, Brandau O, Hengstschläger M.

Asian J Androl. 2012 Mar;14(2):247-50. doi: 10.1038/aja.2011.170. Epub 2012 Jan 9. Review.

44.

Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias.

Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, Stoiber D, Sexl V.

Oncotarget. 2011 Dec;2(12):1043-54.

45.

Tuberin and PRAS40 are anti-apoptotic gatekeepers during early human amniotic fluid stem-cell differentiation.

Fuchs C, Rosner M, Dolznig H, Mikula M, Kramer N, Hengstschläger M.

Hum Mol Genet. 2012 Mar 1;21(5):1049-61. doi: 10.1093/hmg/ddr535. Epub 2011 Nov 16.

PMID:
22090422
46.

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M.

Clin Cancer Res. 2011 Dec 15;17(24):7816-27. doi: 10.1158/1078-0432.CCR-11-0408. Epub 2011 Oct 20.

47.

Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis.

Rosner M, Dolznig H, Schipany K, Mikula M, Brandau O, Hengstschläger M.

Oncotarget. 2011 Sep;2(9):705-12.

48.

Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction.

Dolznig H, Rupp C, Puri C, Haslinger C, Schweifer N, Wieser E, Kerjaschki D, Garin-Chesa P.

Am J Pathol. 2011 Jul;179(1):487-501. doi: 10.1016/j.ajpath.2011.03.015. Epub 2011 Apr 30.

49.

NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells.

Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, Kalt R, Krieger S, Vo TP, Madlener S, Bauer S, Marian B, Hämmerle M, Kretschy N, Teichmann M, Hantusch B, Stary S, Unger C, Seelinger M, Eger A, Mader R, Jäger W, Schmidt W, Grusch M, Dolznig H, Mikulits W, Krupitza G.

Br J Cancer. 2011 Jul 12;105(2):263-71. doi: 10.1038/bjc.2011.194. Epub 2011 May 31.

50.

Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse.

Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R, Hantusch B, Keller T, Nagy-Bojarszky K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S, Madlener S, Vonach C, Davidovits A, Nosaka H, Hämmerle M, Viola K, Dolznig H, Schreiber M, Nader A, Mikulits W, Gnant M, Hirakawa S, Detmar M, Alitalo K, Nijman S, Offner F, Maier TJ, Steinhilber D, Krupitza G.

J Clin Invest. 2011 May;121(5):2000-12. doi: 10.1172/JCI44751. Epub 2011 Apr 11.

Supplemental Content

Loading ...
Support Center